Technology ID
TAB-4658
Cell Line for Adult T-cell Leukemia with Stable Co-expression of CD4 and CD8 for the Development of Therapeutics
E-Numbers
E-117-2020-0
Lead Inventor
Guenthner, Patricia
Lead IC
CDC
Co-Inventors
Lal, Altaf
Lam, Lee
Folks, Thomas
Lairmore, Michael
Hodge, Thomas
Rowe, Thomas
ICs
CDC
Applications
Therapeutics
Research Materials
Therapeutic Areas
Oncology
Development Stages
Pre-Clinical (in vitro)
Research Products
Human Cell Lines
This technology includes a cell line of Adult T-cell Leukemia (ATL) which contains a full-length copy of the HTLV-I genome and dually expressed CD4 and CD8, which can be used for developing therapeutics against HIV and other diseases which may involve interaction with dual-positive T-cells. This cell line can also be used to study the regulation of various cellular genes by HTLV-I since it contains a single integrated copy of the virus expressing all of the viral gene products. This cell line can be used to determine the efficacy of various pharmaceutical agents and has wide potential for application.
Commercial Applications
This cellular model could prove invaluable in determining the efficacy of pharmaceutical agents against HIV and other diseases which might involve interaction with dual-positive T-cells.
Competitive Advantages
Stable co-expression of CD4 and CD8 is a valuable tool for studying the function of the dual CD4/CD8 population that exists in the peripheral blood.
Licensing Contact: